16 results about "Antibody secretion" patented technology

The present disclosure relates to methods for characterizing small amounts of immunogen-binding proteins, such as immunogen-binding antibodies, obtained directly from the supernatant of individually cultured B cells. These methods involve providing a preparation of B cells that avoid hybridoma formation and secrete immunogen-binding antibodies, and individually culturing the B cells under conditions suitable for the B cells to secrete the immunogen-binding antibodies into the culture supernatant. The culture supernatant containing the secreted antibodies is collected from the individually cultured B cells and subjected to one or more binding assays to characterize the immunogen-binding antibodies from the B cell preparation (e.g., for their binding affinity by exposing the cell culture supernatant to increasing concentrations of immunogen).

The invention discloses an application of a Pik3cb inhibitor in treatment of Sjogren's disease. Experiments prove that the Pik3cb inhibitor TGX-221 can reduce the number, activation and chemotaxis of NOD mouse B cells of a Sjogren's disease model mouse, plasma cell differentiation and antibody secretion, improve the immune microenvironment of the submaxillary gland of the Sjogren's disease model mouse, reduce the infiltration degree of submaxillary gland lymphocytes and promote the salivary secretion function; and after the Pik3cb is over-expressed, the symptom and pathology of the Sjogren's disease are aggravated. Therefore, the Pik3cb inhibitor can be used for treating the Sjogren's disease. The invention provides a new thought for research and development of medicines for treating the Sjogren's disease, and has important application value.

The application discloses a kind of green feed additive and preparation method thereof, the green feed additive, including the following mass parts of component: sugar terpenoid 30-50 parts, peach leaf extract 8-12 parts and birch truffle extract 0.1-0.5 parts.The application is compounded with sugar terpenoid, peach leaf extract and birch truffle extract, wherein, sugar terpenoid is the natural active substance extracted from camellia plant oil seed cake, peach leaf extract and birch truffle extract are both traditional Chinese medicine extract, the three are compounded, which will not cause bacterial drug resistance, and can reduce the hidden trouble of food safety;Make the weight of broiler chicken increase fast, have obvious weight gain effect to broiler chicken, and feed to weight ratio is reduced by 30.19%, significantly improve the growth performance of broiler chicken;Can enhance immunity, promote antibody secretion, accelerate immune cell proliferation, enhance antigen antibody level, to realize the rapid protection to broiler chicken.

This invention discloses the application of elamod in the preparation of drugs for treating neuromyelitis optica spectrum disorders (NMOSD). For the first time, in vivo animal experiments have demonstrated that elamod can significantly inhibit the production of pathogenic AQP4 antibodies in NMOSD model mice, improve motor function, retinal and optic nerve function, and reduce myelin damage. Unlike existing B-cell depletion monoclonal antibody therapies, elamod employs a "non-depletion" regulatory mode, inhibiting B-cell activation and antibody secretion without directly eliminating B cells, thus preserving some immune surveillance function and reducing the risk of long-term infection. Ailamod is an oral small molecule drug, included in the national medical insurance program, inexpensive, with no immunogenicity risk, and significantly better patient compliance than injectable monoclonal antibodies. This invention provides a novel, highly effective, and specific targeted drug for NMOSD, possessing significant clinical translational value.

The invention relates to the field of biological medicine, and relates to application of an interferon receptor 1 monoclonal antibody in preparation of a medicine for treating neuromyelitis optica pedigree diseases and a medicine composition. The antibody regulates immune response by inhibiting abnormal activation of an I-type interferon signal channel and down-regulating interferon stimulation gene expression, so that central nervous system inflammation and demyelination injury are relieved. The humanized IFNAR1 monoclonal antibody is independently used; the compound is combined with a B cell targeting drug to synergistically inhibit B cell activation and antibody secretion; and a bispecific antibody targeting IFNAR1 and a transferrin receptor is constructed, so that the ability of the drug to pass through the blood brain barrier is enhanced, and the concentration of the drug in the brain is improved. In-vivo and in-vitro experiments prove that the treatment scheme can effectively reduce the size of the focus of the NMOSD model and improve the neurological function, and a new precise treatment strategy is provided for AQP4 antibody positive patients.

The invention relates to the technical field of biology, in particular to a hybridoma cell strain capable of stably secreting a monoclonal antibody resisting porcine epidemic diarrhea virus (PEDV), the monoclonal antibody secreted by the cell strain, and application of the cell strain and the antibody in PEDV detection. The hybridoma cell strain is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC No.46718. The hybridoma cell strain can be stably passed to 30 generations, still keeps a good cell growth state and excellent antibody secretion ability, and provides a reliable cell source for large-scale production. The antibody is only combined with PEDV without cross reaction, so that the detection accuracy is improved. A detection method established based on the antibody is high in sensitivity, capable of detecting low-concentration antibodies and suitable for early infection diagnosis. The antibody can be used for various detection platforms such as ELISA (enzyme-linked immunosorbent assay), chemiluminescence and the like, and has a good industrialization prospect.

The application discloses a neutralizing nucleic acid aptamer capable of specifically combining with human APRIL and application thereof in inhibiting antibody secretion. The neutralizing nucleic acid aptamer of the application can efficiently neutralize extracellular APRIL molecules in vitro and in vivo, thereby blocking the combination of the molecules with a human calcium-binding cyclophilin ligand-interacting molecule (TACI) and a B cell maturation antigen (BCMA) on a B cell membrane, and finally inhibiting the generation and secretion of antibodies. Compared with the existing biological preparation atacicept for targeting and neutralizing APRIL, the APRIL neutralizing nucleic acid aptamer involved in the application has the advantages of high specificity, high affinity, low immunogenicity and low cost, is a novel nucleic acid drug preparation for inhibiting antibody secretion, and has a great clinical application prospect.

The invention relates to an anti-OXA-23 type carbapenemase monoclonal antibody and a preparation method thereof, and discloses nucleotide sequences and amino acid sequences of a heavy chain variable region and a light chain variable region of the anti-OXA-23 type carbapenemase monoclonal antibody, and a preparation method of the anti-OXA-23 type carbapenemase monoclonal antibody. The anti-OXA-23 carbapenemase monoclonal antibody provided by the invention is high in affinity, strong in specificity, good in stability and stable in antibody secretion capacity, can quickly and specifically recognize OXA-23 recombinant protein, lays a foundation for establishment of a quick detection technology of OXA-23 carbapenemase, and has wide application prospects. And the kit has a wide application value in carbapenemase typing related immunodetection.

The invention discloses a PD-1 antibody secreting type PB-CAR-T cell targeting c-Met and application, and relates to the technical field of tumor immunotherapy, a chimeric antigen receptor CAR sequence containing a PD-1 single-chain antibody scFv and c-Met scFv is integrated into a T cell genome through a PiggyBac transposon system, and the CAR sequence comprises a PD-1 antibody secreting structural domain and a c-Met antigen binding structural domain; a PD-1 antibody secretion structural domain and a c-Met targeted CAR sequence are efficiently integrated into a T cell through a PiggyBac transposon system non-viral vector, the multiplication capacity, tumor killing efficiency and memory phenotype proportion of the CAR-T cell are remarkably improved, meanwhile, immune checkpoints are blocked through local secretion of a PD-1 antibody, immunosuppression in a solid tumor microenvironment is overcome, the risk of immune escape is reduced, and the CAR-T cell has a good application prospect. Compared with a traditional lentiviral vector, the method has the advantages of being high in safety, low in cost and simplified in preparation process, and a new strategy with more clinical transformation potential is provided for treatment of the c-Met positive solid tumor.

The present application relates to the technical field of biology, in particular to a kind of anti-pig CD82 protein monoclonal antibody, hybridoma cell strain and application, monoclonal antibody is expressed and purified using prokaryotic expression system to CD82 (EC2) region, the recombinant protein after purification is prepared as immunogen, is screened by indirect ELISA and Flow Cytometry, obtains a monoclonal cell strain of IgG2a type antibody secretion, the antibody after purification is detected by indirect ELISA method, antibody concentration is to 31.25ng / ml Still have sensitive response, the PAM cell capable of expressing endogenous CD82 protein is detected by flow cytometry, and the results show that mAb has good marking ability to PAM cell, it is explained that CD82 protein can be used for the preparation of mAb of flow cytometry, and the function and mechanism of CD82 protein are further analyzed, and biological tool is provided.

The invention is applicable to the technical field of immunology and cell culture, and provides a single B cell in-vitro culture method which comprises the following steps: S1, preparing peripheral blood mononuclear cells; s2, constructing a single cell distribution method; s3, preparing a combined factor single B cell culture medium and culturing single B cells; s4, microenvironment parameters are controlled; s5, evaluating the cell state; single cell sorting is achieved through an innovative gradient dilution method, a standardized recombinant protein factor combination is adopted to replace cell co-culture, refined low-oxygen microenvironment control is introduced, an integrated culture system is constructed, the in-vitro survival rate of single B cells can be effectively increased, the function maintenance time can be prolonged, the antibody secretion capacity can be stabilized, and the cell quality can be improved. And the equipment dependence and the operation complexity are obviously reduced.

The invention discloses an application of arginine in promoting micropterus salmoides to resist nocardia seriolae infection, which is characterized in that the arginine is used as a functional additive to feed the micropterus salmoides for 8 weeks, then a challenge experiment is carried out, and the influence of the arginine on the nocardia seriolae infection resistance of the micropterus salmoides is explored; comprising high-throughput omics conjoint analysis, mTORC1 pathway activity, antibody content, cell death, tissue structure, survival rate and the like. Researches find that arginine significantly activates an mTORC1 signal channel of micropterus salmoides, and promotes secretion of an IgM antibody in serum to resist nocardia seriola infection; the arginine also inhibits cell death caused by excessive activation of NLRP3 inflammasomes of the micropterus salmoides, so that the micropterus salmoides keeps complete liver, head-kidney and body-kidney structures after being infected by nocardia seriola, and finally the survival rate of the micropterus salmoides after being infected by nocardia seriola is improved. Therefore, the arginine can be used as a functional feed additive for enhancing the capability of the largemouth bass for resisting nocardia seriolae infection.

Disclosed is a method for modifying a fibroblast. The method comprises the following steps: collecting peripheral blood from a healthy person, extracting peripheral blood mononuclear cells from the peripheral blood in vitro by using a lymphocyte separation medium, and sorting and purifying B cells by using immunomagnetic beads; and constructing human CXCL13, TNFSF13B and VCAM1 overexpression plasmids by using molecular cloning technology, and infecting MRC-5 with a lentivirus to obtain an MRC-5 fibroblast simultaneously overexpressing CXCL13, TNFSF13B and VCAM1. Further provided is a modified fibroblast obtained on the basis of the method. Further provided is the use of the modified fibroblast in terms of inducing B-cell chemotaxis, inducing B-cell adhesion and promoting antibody secretion in B cells. The modified fibroblast can be used in the chemotaxis and adhesion of B cells, promotes antibody secretion in B cells, and has good clinical application value.

The present invention relates to methods and compositions for engineering B cells to express transgenic B cell receptor (BCR) for antigen-induced antibody secretion, compositions, methods and uses thereof in immunotherapy.

Provided are a B-cell immortalization-based method for developing a single B-cell antibody and the use thereof. The provided method comprises the following steps: S1, antigen preparation; S2, antigen immunization; S3, modification of a lentiviral vector; S4, viral infection and cell sorting; S5, screening for cells with a high binding activity; S6, sequencing of an antibody sequence; S7, activity verification of a target antibody, etc. The provided antibody development method effectively solves the problems that single B-cell antibody development requires extensive recombinant expression and incurs a high verification cost. By combining single B-cell technology with B-cell immortalization technology, a B cell is infected by using a modified lentivirus, so that the cell achieves immortalization and enables in vitro proliferation and antibody secretion. Furthermore, by combining high-throughput microfluidic screening with cell immortalization technology, cell infection is performed directly in an oil droplet, thereby achieving high-throughput and low-cost antibody development.

The invention discloses a neutralizing nucleic acid aptamer capable of being specifically combined with human APRIL and application of the neutralizing nucleic acid aptamer in inhibition of antibody secretion. The neutralizing aptamer disclosed by the invention can efficiently neutralize extracellular APRIL molecules in vivo and in vitro so as to block the combination of the APRIL molecules with human calcium regulatory cyclophilin ligand interaction molecules (TACI) and B cell maturation antigen (BCMA) on a B cell membrane and finally inhibit the generation and secretion of an antibody. Compared with the existing biological agent tetrobercept for targeted neutralization of APRIL, the APRIL neutralization aptamer provided by the invention has the advantages of strong specificity, high affinity, low immunogenicity, low cost and the like, is a novel nucleic acid medicinal preparation for inhibiting antibody secretion, and has a relatively great clinical application prospect.